Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (12)	7/12/2006 6:44:28 PM
From: keokalani'nui	Read Replies (2) \| Respond to of 285

ibutilide has 8%+ rate of V-tach, QTc, TdP. x1245 has 0% so far. x1245, if you treat recent onset AF, the conversion rate goes up to 52%. (Chronic AF conversion rate--small N, is 8%). I have been thinking the market for x1245 is as big as its safety profile. But just maybe, listening to you--which in my opinion pays--the advertised SEs of existing agents is a big boogey man the company has created for its shareholders. Not expecting a response, since I think you're tired of this thread, but did your colleagues assume x1245 has the same SE profile as current iv SoC? Or that ibutilide SEs are no biggie? Could explain some things.

To: former_pgs who wrote (12)	7/12/2006 9:35:45 PM
From: zeta1961	Respond to of 285

PGS, I hear what you're saying..however, someone going into AF is usually not an acute, must intervene stat, situation..unless of course the folk that come thru the ER waited too long..I do know that for some patients, as long as the ventricular rate is good[using anti-arrhythics if needed], other vital signs good, they'll let the patient hang in AF if the first set of interventions to break the AF don't work..but yes, a patient whose cardiac output is decompensating, and not responding to first-line antiarrhymics, I'd go for the paddles..as I know the cardio's do this.. Your point about it being compared to placebo vs. head to head with current is an important one I will heed.. Amiodorone is aweful re: SE's..I mean aweful.. it has a long half-life so it takes a while to get the right level and takes on average of 3 months to completely clear out!(I think this is what they meant by 'skillful', can cause many other organ issues, patients feel like crap on it, on and on..I haven't consulted a cardiologist on this recently but I can't imagine the doc's not welcoming something like RSD and its SE profile with even non-inferiority.. I'm wondering whether the doc's at your center, because it is a world heart center, have been desensitized to the complexity of what they do and that there are relatively few hospital ER's that can handle what they do every day.. Thanks for pointing to the efficacy data and lack of head to head..this deserves attention Elisabeth